1. Japan Stocks

  2. •

    Consumer Defensive

  3. •

    Household & Personal Products
Rohto Pharmaceutical Co.,Ltd.

Rohto Pharmaceutical Co.,Ltd.

RPHCF
Rohto Pharmaceutical Co.,Ltd.US flagOther OTC
15.00
USD
- -
- -
3.39BMarket Cap
Rohto Pharmaceutical Co.,Ltd.
RPHCF
(Other OTC)

Recent

price

15.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
482.25
490.13
512.07
547.1
621.2
669.64
732.27
679.04
754.04
805.9
825.92
793.6
875.1
1,046.13
1,187.18
1,354.8
626.7
Revenue per Share
33.03
33.87
34.8
34.39
38.57
38.03
40.02
43.97
40.77
43
67.56
73.39
92.61
115.62
135.6
136.11
62.87
Basic EPS, GAAP
43.7
17.6
7.27
48.04
51.53
31.48
29
41.5
60.14
65.06
55.27
42.54
69.79
92.12
111.04
115.7
- -
Free Cash Flow per Basic Share
7
7
8
8
9.12
9.03
10.02
10.01
11
11
13.5
13
15
20.5
24
31.04
- -
Dividend per Share
285.78
314.29
341.11
366.04
400.6
434.96
462.23
495.08
522.8
554.76
607.2
666.32
739.93
835.06
946.37
1,031.36
968.06
Book Value per Share
301.3
320.71
345.92
390.17
413.03
467.61
474.02
508.5
545.7
564.35
591.46
651.87
764.67
900.83
1,042.42
945.43
904.63
Tangible Book Value per Share
235
235
235
235
232
227
227
228
228
228
228
228
228
228
228
228
228
Basic Weighted Avg Shares
113,430
115,262
120,423
128,666
144,082
151,994
166,477
154,599
171,795
183,672
188,375
181,053
199,646
238,664
270,840
308,625
142,971
Sales/Revenue/Turnover
19.94
20.64
11.32
11.18
11.68
8.66
9.42
10
11.11
11.33
11.98
12.7
14.54
14.23
14.79
12.62
13.35
Operating Margin (%)
5,570
4,461
5,136
5,448
5,926
6,341
6,448
5,923
5,914
6,404
6,937
6,748
7,689
7,801
8,687
13,143
- -
Depreciation Expense
7,768
7,966
8,184
8,087
8,947
8,631
9,098
10,011
9,289
9,799
15,410
16,743
21,127
26,377
30,936
31,006
14,342
Net Income, GAAP
37.38
40.9
42.19
40.56
38.71
37.26
36.47
32.12
44.49
39.76
29.67
27.11
23.99
22.92
24.38
26.88
23.21
Effective Tax Rate (%)
6.85
6.91
6.8
6.29
6.21
5.68
5.47
6.48
5.41
5.34
8.18
9.25
10.58
11.05
11.42
10.05
10.03
Profit Margin (%)
23,296
23,359
26,345
27,913
26,338
36,085
42,395
47,526
48,718
55,642
68,589
76,600
92,818
110,084
127,672
123,271
93,749
Working Capital
4,621
2,716
3,335
1,578
1,666
1,074
994
1,765
1,702
1,424
5,190
5,787
13,350
7,516
5,190
43,188
20,236
LT Debt
73,672
77,911
83,624
93,769
98,626
110,513
111,268
118,435
128,437
132,187
140,030
156,611
183,992
215,076
247,033
271,438
264,344
Total Equity
17.42
16.31
8.6
8.55
9.53
7.05
8.19
8.47
7.98
8.94
10.77
10.35
11.63
11.86
12.18
9.61
5.15
Return on Invested Capital (%)
10.98
10.55
9.88
8.96
9.2
8.29
8.39
8.81
7.64
7.64
11.2
10.95
11.92
13.14
14.09
12.13
5.71
Return on Capital (%)
12.11
11.29
10.62
9.73
10
9.01
8.93
9.19
8.01
7.98
11.63
11.53
13.17
14.68
15.22
13.75
6.75
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
5,304
- -
24,300
LT Borrowings
5,190
- -
20,236
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
228
- -
228
Market Capitalization
707,943
752,488
699,103

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
214,759
- -
204,895
Cash, Cash Equivalents & STI
89,210
- -
64,502
Accounts Receivable, Net
44,744
- -
48,694
Inventories
46,657
- -
61,859
Total Current Liabilities
87,087
- -
111,146
Payables & Accruals
- -
- -
- -
ST Debt
5,304
- -
24,300
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.54%
14.19%
9.88%
Free Cash Flow
17.15%
19.52%
4.04%
Net Income, GAAP
14.82%
15.44%
0.23%
Sales/Revenue/Turnover
7.63%
10.67%
13.95%
Total Cash Common Dividend
- -
18.93%
29.17%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
61,171
66,698
73,294
69,677
270,840
2025
- -
- -
- -
- -
308,625
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
39.84
- -
- -
- -
135.6
2025
- -
- -
- -
- -
136.11
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
24
2025
- -
- -
- -
- -
31.04
2026
- -
- -
- -
- -
- -
Similar Companies
Skin Elements Limited (SKN.AX)
KOSÉ Corporation (4922.T)
Unicharm Corporation (UNICY)
Buka Investments Limited (ILE.JO)
Kao Corporation (KAOOY)
European Wax Center, Inc. (EWCZ)
Business
Rohto Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. Founded in 1899 and headquartered in Ikuno-ku, Osaka, Japan, the company operates in over 110 countries across Japan, the Americas, Europe, and Asia, with subsidiaries including The Mentholatum Company and Rohto Nitten; it lists on the Tokyo Stock Exchange Prime Market under ticker 4527. Core products and services encompass over-the-counter (OTC) drugs such as eye drops, eyewash, gastrointestinal medicines, and herbal supplements; skincare offerings including functional cosmetics, sunscreens, lip balms, medicated shampoos like Selsun and GYUTTO, and premium lines such as Hadalabo, Melano CC, and Episteme Stem Science series; functional foods and supplements under brands like Rohto V5; ophthalmology products comprising ethical medicines, medical devices, and contact lens care; regenerative medicines utilizing stem cells for unmet needs in dermatology and orthopedics, including Autologel PRP therapy; and contract development and manufacturing organization (CDMO) services in biotechnology. Recent developments include the 2024 acquisition of a 51% stake in Austria's Sigmapharm/MoNo chem-pharm group for approximately EUR 30 million to bolster European ophthalmology production and distribution; the April 2024 joint acquisition with Mitsui of Singapore-based Eu Yan Sang International to expand into natural health and wellness via traditional Chinese medicine and botanicals, enhancing the Rohto V5 supplement line; a capital and business alliance with Medical PST announced in August 2025; the January 2025 launch of Autologel for refractory ulcers; issuance of zero-coupon convertible bonds in February 2025 to fund growth investments and share repurchases; and disclosure of a medium- to long-term growth strategy in May 2025 targeting diversified expansion in cosmetics, OTC, regenerative medicine, and global markets through 2035, underpinned by ¥50 billion in planned M&A by 2030.